Search

Your search keyword '"Verduri, Alessia"' showing total 144 results
Start Over Author "Verduri, Alessia"
144 results on '"Verduri, Alessia"'

3. Influence of frailty on cardiovascular events and mortality in patients with Chronic Obstructive Pulmonary Disease (COPD): Study protocol for a multicentre European observational study.

Author

Verduri, Alessia, Clini, Enrico, Carter, Ben, and Hewitt, Jonathan

Subjects
*CHRONIC obstructive pulmonary disease, *FRAILTY, *INHALERS, *RESEARCH protocols, *POISSON regression, *MORTALITY
Abstract

Background: Frailty is a clinical state that increases susceptibility to minor stressor events. The risk of frailty is higher in chronic conditions, such as Chronic Obstructive Pulmonary Disease (COPD). Recent studies on COPD have shown that patients living with frailty have an increased risk of mortality. The presence of cardiovascular diseases or conditions are common in COPD and may increase the risk of death. Methods: This protocol describes a European prospective cohort study of community-based people, in a stable condition with diagnosis of COPD (as defined by GOLD guidelines) across hospitals in Italy and UK. Frailty prevalence will be assessed using the Clinical Frailty Scale. At 1- and 2-year follow up, primary outcome will be the impact of frailty on the number of cardiovascular events; secondary outcomes: the influence of frailty on cardiovascular mortality, all-cause mortality, and deaths due to COPD. For the primary outcome a zero-inflated Poisson regression will compare the number of cardiovascular events at 1 year. Secondary outcomes will be analysed using the time to mortality. Discussion: This multicentre study will assess the association between frailty and cardiovascular events and mortality in population with COPD. Data collection is prospective and includes routine clinical data. This research will have important implications for the management of patients with COPD to improve their quality of care, and potentially prognosis. Trial registration number: NCT05922202 (www.clinicaltrials.gov). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Author

Davey, Charlotte, Jones, Sheila, Lunstone, Kiah, Cavenagh, Alice, Silver, Charlotte, Telford, Thomas, Simmons, Rebecca, Mutasem, Tarik El Jichi, Singh, Sandeep, Paxton, Dolcie, Harris, Will, Galbraith, Norman, Bhatti, Emma, Edwards, Jenny, Duffy, Siobhan, Bisset, Carly, Alexander, Ross, Garcia, Madeline, Sangani, Shefali, Kneen, Thomas, Lee, Thomas, McGovern, Aine, Guaraldi, Giovanni, Hewitt, Jonathan, Carter, Ben, Vilches-Moraga, Arturo, Quinn, Terence J, Braude, Philip, Verduri, Alessia, Pearce, Lyndsay, Stechman, Michael, Short, Roxanna, Price, Angeline, Collins, Jemima T, Bruce, Eilidh, Einarsson, Alice, Rickard, Frances, Mitchell, Emma, Holloway, Mark, Hesford, James, Barlow-Pay, Fenella, Clini, Enrico, Myint, Phyo K, Moug, Susan J, and McCarthy, Kathryn

Published
2020
Full Text
View/download PDF

7. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis

Author

Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Annane, Djillali, Reinhart, Konrad, Falsey, Ann R, Branche, Angela, Damas, Pierre, Nijsten, Maarten, de Lange, Dylan W, Deliberato, Rodrigo O, Oliveira, Carolina F, Maravić-Stojković, Vera, Verduri, Alessia, Beghé, Bianca, Cao, Bin, Shehabi, Yahya, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A H, Beishuizen, Albertus, Girbes, Armand R J, de Jong, Evelien, Briel, Matthias, and Mueller, Beat

Published
2018
Full Text
View/download PDF

9. Quality of life and intrinsic capacity in patients with post-acute COVID-19 syndrome is in relation to frailty and resilience phenotypes

Author

Guaraldi, Giovanni, primary, Milic, Jovana, additional, Barbieri, Sara, additional, Marchiò, Tommaso, additional, Caselgrandi, Agnese, additional, Motta, Federico, additional, Beghè, Bianca, additional, Verduri, Alessia, additional, Belli, Michela, additional, Gozzi, Licia, additional, Iadisernia, Vittorio, additional, Faltoni, Matteo, additional, Burastero, Giulia, additional, Dessilani, Andrea, additional, Del Monte, Martina, additional, Dolci, Giovanni, additional, Bacca, Erica, additional, Franceschi, Giacomo, additional, Yaacoub, Dina, additional, Volpi, Sara, additional, Mazzochi, Alice, additional, Clini, Enrico, additional, and Mussini, Cristina, additional

Published
2023
Full Text
View/download PDF

10. A Data-Driven Identification of People Recovering from Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Author

Motta, Federico, primary, Milic, Jovana, additional, Guidetti, Veronica, additional, Belli, Michela, additional, Simion, Mattia, additional, Romani, Federico, additional, Beghetto, Barbara, additional, Nardini, Giulia, additional, Roncaglia, Enrica, additional, Sighinolfi, Laura, additional, Cavinato, Silvia, additional, Verduri, Alessia Policlinico Modena Un, additional, Beghe', Bianca, additional, Clini, Enrico, additional, Cossarizza, Andrea, additional, Missier, Paolo, additional, Cattelan, Annamaria, additional, Cesari, Matteo, additional, Mandreoli, Federica, additional, Mussini, Cristina, additional, and Guaraldi, Giovanni, additional

Published
2023
Full Text
View/download PDF

12. Prognostic value of estimated glomerular filtration rate in hospitalised older patients (over 65) with COVID-19: a multicentre, European, observational cohort study

Author

Carter, Ben, Ramsay, Euan A., Short, Roxanna, Goodison, Sarah, Lumsden, Jane, Khan, Amarah, Braude, Philip, Vilches-Moraga, Arturo, Quinn, Terence J., McCarthy, Kathryn, Hewitt, Jonathan, Myint, Phyo K., Bruce, Eilidh, Einarsson, Alice, McCrorie, Kirsty, Aggrey, Ken, Bilan, Jimmy, Hartrop, Kerr, Murphy, Caitlin, McGovern, Aine, Clini, Enrico, Guaraldi, Giovanni, Verduri, Alessia, Bisset, Carly, Alexander, Ross, Kelly, Joanna, Murphy, Caroline, Mutasem, Tarik El Jichi, Singh, Sandeep, Paxton, Dolcie, Harris, Will, Moug, Susan, Galbraith, Norman, Bhatti, Emma, Edwards, Jenny, Duffy, Siobhan, Espinoza, Maria Fernanda Ramon, Kneen, Thomas, Dafnis, Anna, Allafi, Hala, Vidal, Maria Narro, Price, Angeline, Pearce, Lyndsay, Lee, Thomas, Sangani, Shefali, Garcia, Madeline, Davey, Charlotte, Jones, Sheila, Lunstone, Kiah, Cavenagh, Alice, Silver, Charlotte, Telford, Thomas, and Simmons, Rebecca

Subjects
Male, Chronic kidney failure, SARS-CoV-2, RC952-954.6, COVID-19, Prognosis, Dose-response, Cohort Studies, Geriatrics, Mortality, eGFR, Humans, Female, Renal Insufficiency, Chronic, Geriatrics and Gerontology, Aged, Glomerular Filtration Rate
Abstract

Background The reduced renal function has prognostic significance in COVID-19 and it has been linked to mortality in the general population. Reduced renal function is prevalent in older age and thus we set out to better understand its effect on mortality. Methods Patient clinical and demographic data was taken from the COVID-19 in Older People (COPE) study during two periods (February–June 2020 and October 2020–March 2021, respectively). Kidney function on admission was measured using estimated glomerular filtration rate (eGFR). The primary outcomes were time to mortality and 28-day mortality. Secondary outcome was length of hospital stay. Data were analysed with multilevel Cox proportional hazards regression, and multilevel logistic regression and adjusted for individual patient clinical and demographic characteristics. Results One thousand eight hundred two patients (55.0% male; median [IQR] 80 [73–86] years) were included in the study. 28-day mortality was 42.3% (n = 742). 48% (n = 801) had evidence of renal impairment on admission. Using a time-to-event analysis, reduced renal function was associated with increased in-hospital mortality (compared to eGFR ≥ 60 [Stage 1&2]): eGFR 45–59 [Stage 3a] aHR = 1.26 (95%CI 1.02–1.55); eGFR 30–44 [Stage 3b] aHR = 1.41 (95%CI 1.14–1.73); eGFR 1–29 [Stage 4&5] aHR = 1.42 (95%CI 1.13–1.80). In the co-primary outcome of 28-day mortality, mortality was associated with: Stage 3a adjusted odds ratio (aOR) = 1.18 (95%CI 0.88–1.58), Stage 3b aOR = 1.40 (95%CI 1.03–1.89); and Stage 4&5 aOR = 1.65 (95%CI 1.16–2.35). Conclusion eGFR on admission is a good independent predictor of mortality in hospitalised older patients with COVID-19 population. We found evidence of a dose-response between reduced renal function and increased mortality.

Published
2022

13. 1070. Quality of life and intrinsic capacity in patients with post-acute COVID-19 syndrome is in relation to frailty and resilience phenotypes

Author

Guaraldi, Giovanni, primary, Milic, Jovana, additional, Barbieri, Sara, additional, Marchio’, Tommaso, additional, Caselgrandi, Agnese, additional, Motta, Federico, additional, Beghe’, Bianca, additional, Verduri, Alessia, additional, Belli, Michela, additional, Gozzi, Licia, additional, Iadisernia, Vittorio, additional, Faltoni, Matteo, additional, Burastero, Giulia, additional, Dessilani, Andrea, additional, Monte, Martina Del, additional, Bacca, Erica, additional, Franceschi, Giacomo, additional, Yaacoub, Dina, additional, Volpi, Sara, additional, Mazzochi, Alice, additional, Clini, Enrico, additional, and Mussini, Cristina, additional

Published
2022
Full Text
View/download PDF

14. Quality of life and intrinsic capacity in patients with post-acute COVID-19 syndrome is in relation to frailty and resilience phenotypes

Author

Guaraldi, Giovanni, Jovana, Milic, Sara, Barbieri, Tommaso, Marchio', Agnese, Caselgrandi, Motta, Federico, Beghe', Bianca, Verduri, Alessia, Michela, Belli, Gozzi, Licia, Iadisernia, Vittorio, Faltoni, Matteo, Burastero, Giulia, Dessilani, Andrea, DEL MONTE, Martina, Dolci, Giovanni, Bacca, Erica, Franceschi, Giacomo, Yaacoub, Dina, Volpi, Sara, Alice, Mazzochi, Clini, Enrico, and Mussini, Cristina

Subjects
post-acute COVID-19 syndrome (PACS), quality of life, SARS-CoV-2, COVID-19, frailty, resilience
Published
2023

15. Comparison between first and second wave of COVID-19 outbreak in older people. The COPE multicentre European observational cohort study

Author

Verduri, Alessia, Short, Roxanna, Carter, Ben, Braude, Philip, Vilches-Moraga, Arturo, Quinn, Terence J., Collins, Jemima, Lumsden, Jane, McCarthy, Kathryn, Evans, Louis, Myint, Phyo K., Hewitt, Jonathan, Clini, Enrico, Rickard, Frances, Hesford, James, Mitchell, Emma, Hartrop, Kerr, Murphy, Caitlin, Aggrey, Ken, Bilan, Jimmy, Quinn, Thomas, Kelly, Joanna, Murphy, Caroline, Moug, Susan, Barlow-Pay, Fanella, Khan, Amarah, Espinoza, Maria Fernanda Ramon, Kneen, Thomas, Allafi, Hala, Dafnis, Anna, Vidal, Maria Narro, Price, Angeline, Pearce, Lyndsay, Einarsson, Alice, Bruce, Eilidh, and Mccrorie, Kirsty

Subjects
Aged, 80 and over, Cohort Studies, Male, C-Reactive Protein, Fatigue Syndrome, Chronic, Public Health, Environmental and Occupational Health, COVID-19, Humans, Female, Aged, Disease Outbreaks
Abstract

Background Effective shielding measures and virus mutations have progressively modified the disease between the waves, likewise healthcare systems have adapted to the outbreak. Our aim was to compare clinical outcomes for older people with COVID-19 in Wave 1 (W1) and Wave 2 (W2). Methods All data, including the Clinical Frailty Scale (CFS), were collected for COVID-19 consecutive patients, aged ≥65, from 13 hospitals, in W1 (February–June 2020) and W2 (October 2020–March 2021). The primary outcome was mortality (time to mortality and 28-day mortality). Data were analysed with multilevel Cox proportional hazards, linear and logistic regression models, adjusted for wave baseline demographic and clinical characteristics. Results Data from 611 people admitted in W2 were added to and compared with data collected during W1 (N = 1340). Patients admitted in W2 were of similar age, median (interquartile range), W2 = 79 (73–84); W1 = 80 (74–86); had a greater proportion of men (59.4% vs. 53.0%); had lower 28-day mortality (29.1% vs. 40.0%), compared to W1. For combined W1–W2 sample, W2 was independently associated with improved survival: time-to-mortality adjusted hazard ratio (aHR) = 0.78 [95% confidence interval (CI) 0.65–0.93], 28-day mortality adjusted odds ratio = 0.80 (95% CI 0.62–1.03). W2 was associated with increased length of hospital stay aHR = 0.69 (95% CI 0.59–0.81). Patients in W2 were less frail, CFS [adjusted mean difference (aMD) = −0.50, 95% CI −0.81, −0.18], as well as presented with lower C-reactive protein (aMD = −22.52, 95% CI −32.00, −13.04). Conclusions COVID-19 older adults in W2 were less likely to die than during W1. Patients presented to hospital during W2 were less frail and with lower disease severity and less likely to have renal decline.

Published
2022

17. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome

Author

Milic, Jovana, primary, Barbieri, Sara, additional, Gozzi, Licia, additional, Brigo, Alberto, additional, Beghé, Bianca, additional, Verduri, Alessia, additional, Bacca, Erica, additional, Iadisernia, Vittorio, additional, Cuomo, Gianluca, additional, Dolci, Giovanni, additional, Yaacoub, Dina, additional, Aprile, Emanuele, additional, Belli, Michela, additional, Venuta, Maria, additional, Meschiari, Marianna, additional, Sebastiani, Giada, additional, Clini, Enrico, additional, Mussini, Cristina, additional, Lonardo, Amedeo, additional, Guaraldi, Giovanni, additional, and Raggi, Paolo, additional

Published
2022
Full Text
View/download PDF

19. sj-pdf-1-taw-10.1177_2042098620985690 – Supplemental material for Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19

Author

Phyo K. Myint, Carter, Ben, Barlow-Pay, Fenella, Short, Roxanna, Einarsson, Alice G., Bruce, Eilidh, McCarthy, Kathryn, Verduri, Alessia, Jemima Collins, Hesford, James, Rickard, Frances, Mitchell, Emma, Holloway, Mark, McGovern, Aine, Vilches-Moraga, Arturo, Braude, Philip, Pearce, Lyndsay, Stechman, Michael, Price, Angeline, Quinn, Terence J., Clini, Enrico, Moug, Susan, and Hewitt, Jonathan

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-taw-10.1177_2042098620985690 for Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19 by Phyo K. Myint, Ben Carter, Fenella Barlow-Pay, Roxanna Short, Alice G. Einarsson, Eilidh Bruce, Kathryn McCarthy, Alessia Verduri, Jemima Collins, James Hesford, Frances Rickard, Emma Mitchell, Mark Holloway, Aine McGovern, Arturo Vilches-Moraga, Philip Braude, Lyndsay Pearce, Michael Stechman, Angeline Price, Terence J. Quinn, Enrico Clini, Susan Moug and Jonathan Hewitt in Therapeutic Advances in Drug Safety

Published
2021
Full Text
View/download PDF

20. Multiple House Occupancy is Associated with Mortality in Hospitalised Patients with Covid-19

Author

Bruce, Eilidh, Carter, Ben, Quinn, Terence J, Verduri, Alessia, Pearson, Oliver, Vilches-Moraga, Arturo, Price, Angeline, Mcgovern, Aine, Evans, Louis, Mccarthy, Kathryn, Hewitt, Jonathan, Moug, Susan, Myint, Phyo K, Behalf Of Cope Study Team, Null, Einarsson, Alice, Fleck, Anna, Bisset, Carly, Alexander, Ross, Guaraldi, Giovanni, Murphy, Caroline, Kelly, Joanna, Short, Roxanna, Braude, Philip, El Jichi Mutasem, Tarik, Singh, Sandeep, Paxton, Dolcie, Harris, Will, Hesford, James, Holloway, Mark, Mitchell, Emma, Rickard, Frances, Galbraith, Norman, Bhatti, Emma, Edwards, Jenny, Duffy, Siobhan, Barlow-Pay, Fenella, Pearce, Lyndsey, Garcia, Madeline, Sangani, Shefali, Kneen, Thomas, Lee, Thomas, Davey, Charlotte, Jones, Sheila, Lunstone, Kiah, Cavenagh, Alice, Silver, Charlotte, Telford, Thomas, Simmons, Rebecca, and Stechman, Michael

Subjects
Male, Occupancy, Original Manuscript, Logistic regression, Cohort Studies, Pandemic, Coronavirus, Covid-19, Multiple House occupancy, medicine, Humans, AcademicSubjects/MED00860, AcademicSubjects/SOC01210, Pandemics, Aged, COPD, Proportional hazards model, business.industry, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, medicine.disease, Hospitalization, Heart failure, Population study, Female, business, AcademicSubjects/SOC02610, Demography, Cohort study
Abstract

Background In response to the COVID-19 pandemic, many countries mandated staying at home to reduce transmission. This study examined the association between living arrangements (house occupancy numbers) and outcomes in COVID-19. Methods Study population was drawn from the COPE study, a multicentre cohort study. House occupancy was defined as: living alone; living with one other person; living with multiple other people; or living in a nursing/residential home. Outcomes were time from admission to mortality and discharge (Cox regression), and Day 28 mortality (logistic regression) analyses were adjusted for key comorbidities and covariates including admission: age, sex, smoking, heart failure, admission C-reactive protein (CRP), chronic obstructive pulmonary disease, estimated glomerular filtration rate, frailty and others. Results A total of 1584 patients were included from 13 hospitals across UK and Italy: 676 (42.7%) were female, 907 (57.3%) were male, median age was 74 years (range: 19–101). At 28 days, 502 (31.7%) had died. Median admission CRP was 67, 82, 79.5 and 83 mg/l for those living alone, with someone else, in a house of multiple occupancy and in a nursing/residential home, respectively. Compared to living alone, living with anyone was associated with increased mortality: within a couple [adjusted hazard ratios (aHR) = 1.39, 95% confidence intervals (CI) 1.09–1.77, P = 0.007]; living in a house of multiple occupancy (aHR = 1.67, 95% CI 1.17–2.38, P = 0.005); and living in a residential home (aHR = 1.36, 95% CI 1.03–1.80, P = 0.031). Conclusion For patients hospitalized with COVID-19, those living with one or more people had an increased association with mortality, they also exhibited higher CRP indicating increased disease severity suggesting they delayed seeking care.

Published
2021

21. Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials

Author

Medische Staf Intensive Care, NVIC bedrijfsvoering, Brain, Infection & Immunity, Heilmann, Eva, Gregoriano, Claudia, Annane, Djillali, Reinhart, Konrad, Bouadma, Lila, Wolff, Michel, Chastre, Jean, Luyt, Charles-Edouard, Tubach, Florence, Branche, Angela R, Briel, Matthias, Christ-Crain, Mirjam, Welte, Tobias, Corti, Caspar, de Jong, Evelien, Nijsten, Maarten, de Lange, Dylan W, van Oers, Jos A H, Beishuizen, Albertus, Girbes, Armand R J, Deliberato, Rodrigo O, Schroeder, Stefan, Kristoffersen, Kristina B, Layios, Nathalie, Damas, Pierre, Lima, Stella S S, Nobre, Vandack, Wei, Long, Oliveira, Carolina F, Shehabi, Yahya, Stolz, Daiana, Tamm, Michael, Verduri, Alessia, Wang, Jin-Xiang, Drevet, Sabine, Gavazzi, Gaetan, Mueller, Beat, Schuetz, Philipp, Medische Staf Intensive Care, NVIC bedrijfsvoering, Brain, Infection & Immunity, Heilmann, Eva, Gregoriano, Claudia, Annane, Djillali, Reinhart, Konrad, Bouadma, Lila, Wolff, Michel, Chastre, Jean, Luyt, Charles-Edouard, Tubach, Florence, Branche, Angela R, Briel, Matthias, Christ-Crain, Mirjam, Welte, Tobias, Corti, Caspar, de Jong, Evelien, Nijsten, Maarten, de Lange, Dylan W, van Oers, Jos A H, Beishuizen, Albertus, Girbes, Armand R J, Deliberato, Rodrigo O, Schroeder, Stefan, Kristoffersen, Kristina B, Layios, Nathalie, Damas, Pierre, Lima, Stella S S, Nobre, Vandack, Wei, Long, Oliveira, Carolina F, Shehabi, Yahya, Stolz, Daiana, Tamm, Michael, Verduri, Alessia, Wang, Jin-Xiang, Drevet, Sabine, Gavazzi, Gaetan, Mueller, Beat, and Schuetz, Philipp

Published
2021

22. Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials

Author

Heilmann, Eva, primary, Gregoriano, Claudia, additional, Annane, Djillali, additional, Reinhart, Konrad, additional, Bouadma, Lila, additional, Wolff, Michel, additional, Chastre, Jean, additional, Luyt, Charles-Edouard, additional, Tubach, Florence, additional, Branche, Angela R, additional, Briel, Matthias, additional, Christ-Crain, Mirjam, additional, Welte, Tobias, additional, Corti, Caspar, additional, de Jong, Evelien, additional, Nijsten, Maarten, additional, de Lange, Dylan W, additional, van Oers, Jos A H, additional, Beishuizen, Albertus, additional, Girbes, Armand R J, additional, Deliberato, Rodrigo O, additional, Schroeder, Stefan, additional, Kristoffersen, Kristina B, additional, Layios, Nathalie, additional, Damas, Pierre, additional, Lima, Stella S S, additional, Nobre, Vandack, additional, Wei, Long, additional, Oliveira, Carolina F, additional, Shehabi, Yahya, additional, Stolz, Daiana, additional, Tamm, Michael, additional, Verduri, Alessia, additional, Wang, Jin-Xiang, additional, Drevet, Sabine, additional, Gavazzi, Gaetan, additional, Mueller, Beat, additional, and Schuetz, Philipp, additional

Published
2021
Full Text
View/download PDF

23. Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19

Author

Myint, Phyo K., primary, Carter, Ben, additional, Barlow-Pay, Fenella, additional, Short, Roxanna, additional, Einarsson, Alice G., additional, Bruce, Eilidh, additional, McCarthy, Kathryn, additional, Verduri, Alessia, additional, Collins, Jemima, additional, Hesford, James, additional, Rickard, Frances, additional, Mitchell, Emma, additional, Holloway, Mark, additional, McGovern, Aine, additional, Vilches-Moraga, Arturo, additional, Braude, Philip, additional, Pearce, Lyndsay, additional, Stechman, Michael, additional, Price, Angeline, additional, Quinn, Terence J., additional, Clini, Enrico, additional, Moug, Susan, additional, and Hewitt, Jonathan, additional

Published
2021
Full Text
View/download PDF

24. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19

Author

Braude, Philip, primary, Carter, Ben, additional, Short, Roxanna, additional, Vilches-Moraga, Arturo, additional, Verduri, Alessia, additional, Pearce, Lyndsay, additional, Price, Angeline, additional, Quinn, Terence J., additional, Stechman, Michael, additional, Collins, Jemima, additional, Bruce, Eilidh, additional, Einarsson, Alice, additional, Rickard, Frances, additional, Mitchell, Emma, additional, Holloway, Mark, additional, Hesford, James, additional, Barlow-Pay, Fenella, additional, Clini, Enrico, additional, Myint, Phyo Kyaw, additional, Moug, Susan, additional, McCarthy, Kathryn, additional, and Hewitt, Jonathan, additional

Published
2020
Full Text
View/download PDF

26. Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: a patient-level meta-analysis from randomized controlled trials

Author

Heilmann, Eva, primary, Gregoriano, Claudia, additional, Wirz, Yannick, additional, Luyt, Charles-Edouard, additional, Wolff, Michel, additional, Chastre, Jean, additional, Tubach, Florence, additional, Christ-Crain, Mirjam, additional, Bouadma, Lila, additional, Annane, Djillali, additional, Damas, Pierre, additional, Kristoffersen, Kristina B., additional, Oliveira, Carolina F., additional, Stolz, Daiana, additional, Tamm, Michael, additional, de Jong, Evelien, additional, Reinhart, Konrad, additional, Shehabi, Yahya, additional, Verduri, Alessia, additional, Nobre, Vandack, additional, Nijsten, Maarten, additional, deLange, Dylan W., additional, van Oers, Jos A.H., additional, Beishuizen, Albertus, additional, Girbes, Armand R.J., additional, Mueller, Beat, additional, and Schuetz, Philipp, additional

Published
2020
Full Text
View/download PDF

27. The Clinical Frailty Scale: Estimating the Prevalence of Frailty in Older Patients Hospitalised with COVID-19. The COPE Study

Author

Collins, Jemima T., primary, Short, Roxanna, additional, Carter, Ben, additional, Verduri, Alessia, additional, Myint, Phyo K., additional, Quinn, Terence J., additional, Vilches-Moraga, Arturo, additional, Stechman, Michael J., additional, Moug, Susan, additional, McCarthy, Kathryn, additional, and Hewitt, Jonathan, additional

Published
2020
Full Text
View/download PDF

28. Study protocol for the COPE study: COVID-19 in Older PEople: the influence of frailty and multimorbidity on survival. A multicentre, European observational study

Author

Price, Angeline, primary, Barlow-Pay, Fenella, additional, Duffy, Siobhan, additional, Pearce, Lyndsay, additional, Vilches-Moraga, Arturo, additional, Moug, Susan, additional, Quinn, Terry, additional, Stechman, Michael, additional, Braude, Philip, additional, Mitchell, Emma, additional, Myint, Phyo Kyaw, additional, Verduri, Alessia, additional, McCarthy, Kathryn, additional, Carter, Ben, additional, and Hewitt, Jonathan, additional

Published
2020
Full Text
View/download PDF

29. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Author

Hewitt, Jonathan, primary, Carter, Ben, additional, Vilches-Moraga, Arturo, additional, Quinn, Terence J, additional, Braude, Philip, additional, Verduri, Alessia, additional, Pearce, Lyndsay, additional, Stechman, Michael, additional, Short, Roxanna, additional, Price, Angeline, additional, Collins, Jemima T, additional, Bruce, Eilidh, additional, Einarsson, Alice, additional, Rickard, Frances, additional, Mitchell, Emma, additional, Holloway, Mark, additional, Hesford, James, additional, Barlow-Pay, Fenella, additional, Clini, Enrico, additional, Myint, Phyo K, additional, Moug, Susan J, additional, McCarthy, Kathryn, additional, Davey, Charlotte, additional, Jones, Sheila, additional, Lunstone, Kiah, additional, Cavenagh, Alice, additional, Silver, Charlotte, additional, Telford, Thomas, additional, Simmons, Rebecca, additional, Mutasem, Tarik El Jichi, additional, Singh, Sandeep, additional, Paxton, Dolcie, additional, Harris, Will, additional, Galbraith, Norman, additional, Bhatti, Emma, additional, Edwards, Jenny, additional, Duffy, Siobhan, additional, Bisset, Carly, additional, Alexander, Ross, additional, Garcia, Madeline, additional, Sangani, Shefali, additional, Kneen, Thomas, additional, Lee, Thomas, additional, McGovern, Aine, additional, and Guaraldi, Giovanni, additional

Published
2020
Full Text
View/download PDF

30. Routine Use of Immunosuppressants is Associated with Mortality in Hospitalised Patients with COVID-19

Author

Myint, Phyo K, primary, Carter, Ben, additional, Barlow-Pay, Fenella, additional, Short, Roxanna, additional, Einarsson, Alice G, additional, Bruce, Eilidh, additional, McCarthy, Kathryn, additional, Verduri, Alessia, additional, Collins, Jemima, additional, Hesford, James, additional, Rickard, Frances, additional, Mitchell, Emma, additional, Halloway, Mark, additional, McGovern, Aine, additional, Vilches-Moraga, Arturo, additional, Braude, Philip, additional, Pearce, Lyndsay, additional, Stechman, Michael, additional, Price, Angeline, additional, Quinn, Terence J, additional, Clini, Enrico, additional, Moug, Susan J, additional, and Hewitt, Jonathan, additional

Published
2020
Full Text
View/download PDF

31. Multiple house occupancy is associated with mortality in hospitalized patients with COVID-19.

Author

Bruce, Eilidh, Carter, Ben, Quinn, Terence J, Verduri, Alessia, Pearson, Oliver, Vilches-Moraga, Arturo, Price, Angeline, McGovern, Aine, Evans, Louis, McCarthy, Kathryn, Hewitt, Jonathan, Moug, Susan, Myint, Phyo K, and Team, COPE Study

Subjects
RESEARCH, HOSPITAL patients, COVID-19, CONFIDENCE intervals, MEDICAL cooperation, DESCRIPTIVE statistics, HOUSING, LOGISTIC regression analysis, LONGITUDINAL method
Abstract

Background In response to the COVID-19 pandemic, many countries mandated staying at home to reduce transmission. This study examined the association between living arrangements (house occupancy numbers) and outcomes in COVID-19. Methods Study population was drawn from the COPE study, a multicentre cohort study. House occupancy was defined as: living alone; living with one other person; living with multiple other people; or living in a nursing/residential home. Outcomes were time from admission to mortality and discharge (Cox regression), and Day 28 mortality (logistic regression) analyses were adjusted for key comorbidities and covariates including admission: age, sex, smoking, heart failure, admission C-reactive protein (CRP), chronic obstructive pulmonary disease, estimated glomerular filtration rate, frailty and others. Results A total of 1584 patients were included from 13 hospitals across UK and Italy: 676 (42.7%) were female, 907 (57.3%) were male, median age was 74 years (range: 19–101). At 28 days, 502 (31.7%) had died. Median admission CRP was 67, 82, 79.5 and 83 mg/l for those living alone, with someone else, in a house of multiple occupancy and in a nursing/residential home, respectively. Compared to living alone, living with anyone was associated with increased mortality: within a couple [adjusted hazard ratios (aHR) = 1.39, 95% confidence intervals (CI) 1.09–1.77, P  = 0.007]; living in a house of multiple occupancy (aHR = 1.67, 95% CI 1.17–2.38, P  = 0.005); and living in a residential home (aHR = 1.36, 95% CI 1.03–1.80, P  = 0.031). Conclusion For patients hospitalized with COVID-19, those living with one or more people had an increased association with mortality, they also exhibited higher CRP indicating increased disease severity suggesting they delayed seeking care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. The role of C-reactive protein as a prognostic marker in COVID-19.

Author

Stringer, Dominic, Braude, Philip, Myint, Phyo K, Evans, Louis, Collins, Jemima T, Verduri, Alessia, Quinn, Terry J, Vilches-Moraga, Arturo, Stechman, Michael J, Pearce, Lyndsay, Moug, Susan, McCarthy, Kathryn, Hewitt, Jonathan, Carter, Ben, Collaborators, COPE Study, and COPE Study Collaborators

Subjects
COVID-19, ACUTE phase proteins, C-reactive protein, AKAIKE information criterion, MEDICAL personnel, OLDER people
Abstract

Background: C-reactive protein (CRP) is a non-specific acute phase reactant elevated in infection or inflammation. Higher levels indicate more severe infection and have been used as an indicator of COVID-19 disease severity. However, the evidence for CRP as a prognostic marker is yet to be determined. The aim of this study is to examine the CRP response in patients hospitalized with COVID-19 and to determine the utility of CRP on admission for predicting inpatient mortality.Methods: Data were collected between 27 February and 10 June 2020, incorporating two cohorts: the COPE (COVID-19 in Older People) study of 1564 adult patients with a diagnosis of COVID-19 admitted to 11 hospital sites (test cohort) and a later validation cohort of 271 patients. Admission CRP was investigated, and finite mixture models were fit to assess the likely underlying distribution. Further, different prognostic thresholds of CRP were analysed in a time-to-mortality Cox regression to determine a cut-off. Bootstrapping was used to compare model performance [Harrell's C statistic and Akaike information criterion (AIC)].Results: The test and validation cohort distribution of CRP was not affected by age, and mixture models indicated a bimodal distribution. A threshold cut-off of CRP ≥40 mg/L performed well to predict mortality (and performed similarly to treating CRP as a linear variable).Conclusions: The distributional characteristics of CRP indicated an optimal cut-off of ≥40 mg/L was associated with mortality. This threshold may assist clinicians in using CRP as an early trigger for enhanced observation, treatment decisions and advanced care planning. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: A patient level meta-analysis

Author

Infection & Immunity, NVIC bedrijfsvoering, MICU, UMC Utrecht, Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Annane, Djillali, Reinhart, Konrad, Falsey, Ann R, Branche, Angela, Damas, Pierre, Nijsten, Maarten W N, de Lange, Dylan W., Deliberato, Rodrigo O, Oliveira, Carolina F, Maravić-Stojković, Vera, Verduri, Alessia, Beghé, Bianca, Cao, Bin, Shehabi, Yahya, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A H, Beishuizen, Albertus, Girbes, Armand R.J., de Jong, Evelien, Briel, Matthias, Mueller, Beat, Infection & Immunity, NVIC bedrijfsvoering, MICU, UMC Utrecht, Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Annane, Djillali, Reinhart, Konrad, Falsey, Ann R, Branche, Angela, Damas, Pierre, Nijsten, Maarten W N, de Lange, Dylan W., Deliberato, Rodrigo O, Oliveira, Carolina F, Maravić-Stojković, Vera, Verduri, Alessia, Beghé, Bianca, Cao, Bin, Shehabi, Yahya, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A H, Beishuizen, Albertus, Girbes, Armand R.J., de Jong, Evelien, Briel, Matthias, and Mueller, Beat

Published
2018

35. Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: a patient-level meta-analysis from randomized controlled trials.

Author

Heilmann, Eva, Gregoriano, Claudia, Wirz, Yannick, Luyt, Charles-Edouard, Wolff, Michel, Chastre, Jean, Tubach, Florence, Christ-Crain, Mirjam, Bouadma, Lila, Annane, Djillali, Damas, Pierre, Kristoffersen, Kristina B., Oliveira, Carolina F., Stolz, Daiana, Tamm, Michael, de Jong, Evelien, Reinhart, Konrad, Shehabi, Yahya, Verduri, Alessia, and Nobre, Vandack

Subjects
CALCITONIN, KIDNEY physiology, RANDOMIZED controlled trials, ANTIBIOTICS, CHRONIC kidney failure, GLOMERULAR filtration rate
Abstract

Objectives: Patients with impaired kidney function have a significantly slower decrease of procalcitonin (PCT) levels during infection. Our aim was to study PCT-guided antibiotic stewardship and clinical outcomes in patients with impairments of kidney function as assessed by creatinine levels measured upon hospital admission. Methods: We pooled and analyzed individual data from 15 randomized controlled trials who were randomly assigned to receive antibiotic therapy based on a PCT-algorithms or based on standard of care. We stratified patients on the initial glomerular filtration rate (GFR, ml/min/1.73 m2) in three groups (GFR >90 [chronic kidney disease; CKD 1], GFR 15–89 [CKD 2–4] and GFR<15 [CKD 5]). The main efficacy and safety endpoints were duration of antibiotic treatment and 30-day mortality. Results: Mean duration of antibiotic treatment was significantly shorter in PCT-guided (n=2,492) compared to control patients (n=2,510) (9.5–7.6 days; adjusted difference in days −2.01 [95% CI, −2.45 to −1.58]). CKD 5 patients had overall longer treatment durations, but a 2.5-day reduction in treatment duration was still found in patients receiving in PCT-guided care (11.3 vs. 8.6 days [95% CI −3.59 to −1.40]). There were 397 deaths in 2,492 PCT-group patients (15.9%) compared to 460 deaths in 2,510 control patients (18.3%) (adjusted odds ratio, 0.88 [95% CI 0.78 to 0.98)]. Effects of PCT-guidance on antibiotic treatment duration and mortality were similar in subgroups stratified by infection type and clinical setting (p interaction >0.05). Conclusions: This individual patient data meta-analysis confirms that the use of PCT in patients with impaired kidney function, as assessed by admission creatinine levels, is associated with shorter antibiotic courses and lower mortality rates. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. Chronic critical illness in patients with acute respiratory failure admitted to a respiratory intensive care unit

Author

Marchioni, Alessandro, primary, Tonelli, Roberto, additional, Fantini, Riccardo, additional, Tabbì, Luca, additional, Sdanganelli, Antonia, additional, Castaniere, Ivana, additional, Verduri, Alessia, additional, Garofalo, Martina, additional, Cerri, Stefania, additional, Ruggieri, Valentina, additional, and Clini, Enrico, additional

Published
2018
Full Text
View/download PDF

37. Three-Year Hospitalization and Mortality in Elderly Smokers with Chronic Obstructive Pulmonary Disease or Chronic Heart Failure

Author

Beghé, Bianca, primary, Fabbri, Leonardo M., additional, Garofalo, Martina, additional, Schito, Michela, additional, Verduri, Alessia, additional, Bortolotti, Monica, additional, Stendardo, Mariarita, additional, Ruggieri, Valentina, additional, Fucili, Alessandro, additional, Sverzellati, Nicola, additional, Della Casa, Giovanni, additional, Maietti, Elisa, additional, Clini, Enrico M., additional, and Boschetto, Piera, additional

Published
2018
Full Text
View/download PDF

38. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials

Author

Schuetz, Philipp, primary, Bolliger, Rebekka, additional, Merker, Meret, additional, Christ-Crain, Mirjam, additional, Stolz, Daiana, additional, Tamm, Michael, additional, Luyt, Charles E, additional, Wolff, Michel, additional, Schroeder, Stefan, additional, Nobre, Vandack, additional, Reinhart, Konrad, additional, Branche, Angela, additional, Damas, Pierre, additional, Nijsten, Maarten, additional, Deliberato, Rodrigo O., additional, Verduri, Alessia, additional, Beghé, Bianca, additional, Cao, Bin, additional, Shehabi, Yahya, additional, Jensen, Jens-Ulrik S., additional, Beishuizen, Albertus, additional, de Jong, Evelien, additional, Briel, Matthias, additional, Welte, Tobias, additional, and Mueller, Beat, additional

Published
2018
Full Text
View/download PDF

39. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Author

Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Bhatnagar, Neera, Annane, Djillali, Reinhart, Konrad, Branche, Angela, Damas, Pierre, Nijsten, Maarten W N, de Lange, Dylan W, Deliberato, Rodrigo O, Lima, Stella Ss, Maravić-Stojković, Vera, Verduri, Alessia, Cao, Bin, Shehabi, Yahya, Beishuizen, Albertus, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A, Falsey, Ann R, de Jong, Evelien, Oliveira, Carolina F, Beghe, Bianca, Briel, Matthias, Mueller, Beat, Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Bhatnagar, Neera, Annane, Djillali, Reinhart, Konrad, Branche, Angela, Damas, Pierre, Nijsten, Maarten W N, de Lange, Dylan W, Deliberato, Rodrigo O, Lima, Stella Ss, Maravić-Stojković, Vera, Verduri, Alessia, Cao, Bin, Shehabi, Yahya, Beishuizen, Albertus, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A, Falsey, Ann R, de Jong, Evelien, Oliveira, Carolina F, Beghe, Bianca, Briel, Matthias, and Mueller, Beat

Published
2017

40. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Author

Medische Staf Intensive Care, Infection & Immunity, Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Bhatnagar, Neera, Annane, Djillali, Reinhart, Konrad, Branche, Angela, Damas, Pierre, Nijsten, Maarten W N, de Lange, Dylan W, Deliberato, Rodrigo O, Lima, Stella Ss, Maravić-Stojković, Vera, Verduri, Alessia, Cao, Bin, Shehabi, Yahya, Beishuizen, Albertus, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A, Falsey, Ann R, de Jong, Evelien, Oliveira, Carolina F, Beghe, Bianca, Briel, Matthias, Mueller, Beat, Medische Staf Intensive Care, Infection & Immunity, Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Bhatnagar, Neera, Annane, Djillali, Reinhart, Konrad, Branche, Angela, Damas, Pierre, Nijsten, Maarten W N, de Lange, Dylan W, Deliberato, Rodrigo O, Lima, Stella Ss, Maravić-Stojković, Vera, Verduri, Alessia, Cao, Bin, Shehabi, Yahya, Beishuizen, Albertus, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A, Falsey, Ann R, de Jong, Evelien, Oliveira, Carolina F, Beghe, Bianca, Briel, Matthias, and Mueller, Beat

Published
2017

41. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Author

Schuetz, Philipp, primary, Wirz, Yannick, additional, Sager, Ramon, additional, Christ-Crain, Mirjam, additional, Stolz, Daiana, additional, Tamm, Michael, additional, Bouadma, Lila, additional, Luyt, Charles E, additional, Wolff, Michel, additional, Chastre, Jean, additional, Tubach, Florence, additional, Kristoffersen, Kristina B, additional, Burkhardt, Olaf, additional, Welte, Tobias, additional, Schroeder, Stefan, additional, Nobre, Vandack, additional, Wei, Long, additional, Bucher, Heiner C C, additional, Bhatnagar, Neera, additional, Annane, Djillali, additional, Reinhart, Konrad, additional, Branche, Angela, additional, Damas, Pierre, additional, Nijsten, Maarten, additional, de Lange, Dylan W, additional, Deliberato, Rodrigo O, additional, Lima, Stella SS, additional, Maravić-Stojković, Vera, additional, Verduri, Alessia, additional, Cao, Bin, additional, Shehabi, Yahya, additional, Beishuizen, Albertus, additional, Jensen, Jens-Ulrik S, additional, Corti, Caspar, additional, Van Oers, Jos A, additional, Falsey, Ann R, additional, de Jong, Evelien, additional, Oliveira, Carolina F, additional, Beghe, Bianca, additional, Briel, Matthias, additional, and Mueller, Beat, additional

Published
2017
Full Text
View/download PDF

42. Three-Year Hospitalization and Mortality in Elderly Smokers with Chronic Obstructive Pulmonary Disease or Chronic Heart Failure.

Author

Beghé, Bianca, Garofalo, Martina, Verduri, Alessia, Bortolotti, Monica, Ruggieri, Valentina, Clini, Enrico M., Schito, Michela, Stendardo, Mariarita, Boschetto, Piera, Fabbri, Leonardo M., Fucili, Alessandro, Sverzellati, Nicola, Della Casa, Giovanni, and Maietti, Elisa

Subjects
OBSTRUCTIVE lung disease diagnosis, MORTALITY risk factors, AGE distribution, AORTA, BLOOD testing, CHRONIC diseases, COMPUTED tomography, EX-smokers, GLOMERULAR filtration rate, HEALTH care teams, HOSPITAL care, HEART failure, HOSPITAL admission & discharge, KIDNEY diseases, OBSTRUCTIVE lung diseases, PATIENTS, PERIPHERAL vascular diseases, RESPIRATORY measurements, SMOKING, COMORBIDITY, METABOLIC syndrome, DISEASE prevalence, CALCINOSIS, DIAGNOSIS
Abstract

Background: In elderly smokers, chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) usually present with dyspnoea. COPD and CHF are associated -almost invariably with concomitant chronic diseases, which contribute to severity and prognosis. Objectives: We investigated similarities and differences in the clinical presentation, concomitant chronic diseases and risk factors for -mortality and hospitalization at 3-year follow-up in elderly smokers/ex-smokers with a primary diagnosis of COPD or CHF recruited and followed in specialized centers. Methods: We examined 144 patients with COPD and 96 with CHF, ≥65 years, ≥20 pack/years, and measured COPD Assessment Test (CAT) score, modified Medical Research Council, NYHA, and Charlson Index, routine blood test, estimated glomerular filtration rate, HRCT scan, 6-min walk test. In addition, in each patient we actively searched for CHF, COPD, peripheral vascular disease, and metabolic syndrome. Results: COPD and CHF patients had mild to moderate disease, but the majority was symptomatic. Comorbidities were highly prevalent and often unrecognized in both groups. COPD and CHF patients had a similar risk of hospitalization and death at 3 years. Lower glomerular filtration rate, shorter 6MWT, and ascending aorta calcification score ≥2 were independent predictors of mortality in COPD, whereas previous 12 months hospitalizations, renal disease, and heart diameter were in CHF patients. Lower glomerular filtration rate value, higher CAT score, and lower FEV1/FVC ratio were associated with hospitalization in COPD, while age, lower FEV1% predicted, and peripheral vascular disease were in CHF. Conclusions: There are relevant similarities and differences between patients with COPD and CHF even when admitted to specialized outpatient centers, suggesting that these patients should be manage in multidisciplinary units. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. LATE-BREAKING ABSTRACT: Risk factors for hospitalization and death in elderly smokers with chronic obstructive pulmonary disease (COPD) and/or chronic heart failure (CHF)

Author

Verduri, Alessia, primary, Beghé, Bianca, additional, Garofalo, Martina, additional, Balduzzi, Sara, additional, Schito, Michela, additional, Ruggieri, Valentina, additional, Fucili, Alessandro, additional, Fabbri, Leonardo M., additional, Clini, Enrico, additional, and Boschetto, Piera, additional

Published
2016
Full Text
View/download PDF

45. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: A randomized noninferiority trial

Author

Verduri, A, Luppi, F, D'Amico, R, Balduzzi, S, Vicini, R, Liverani, A, Ruggieri, V, Plebani, M, Barbaro, M, Spanevello, A, Canonica, G, Papi, A, Fabbri, L, Beghè, B, Verduri, Alessia, Luppi, Fabrizio, D'Amico, Roberto, Balduzzi, Sara, Vicini, Roberto, Liverani, Anna, Ruggieri, Valentina, Plebani, Mario, Barbaro, Maria Pia Foschino, Spanevello, Antonio, Canonica, Giorgio Walter, Papi, Alberto, Fabbri, Leonardo Michele, Beghè, Bianca, Verduri, A, Luppi, F, D'Amico, R, Balduzzi, S, Vicini, R, Liverani, A, Ruggieri, V, Plebani, M, Barbaro, M, Spanevello, A, Canonica, G, Papi, A, Fabbri, L, Beghè, B, Verduri, Alessia, Luppi, Fabrizio, D'Amico, Roberto, Balduzzi, Sara, Vicini, Roberto, Liverani, Anna, Ruggieri, Valentina, Plebani, Mario, Barbaro, Maria Pia Foschino, Spanevello, Antonio, Canonica, Giorgio Walter, Papi, Alberto, Fabbri, Leonardo Michele, and Beghè, Bianca

Abstract

The duration of antibiotic treatment of exacerbations of COPD (ECOPD) is controversial. Serum procalcitonin (PCT) is a biomarker of bacterial infection used to identify the cause of ECOPD. METHODS AND FINDINGS: We investigated whether a PCT-guided plan would allow a shorter duration of antibiotic treatment in patients with severe ECOPD. For this multicenter, randomized, non-inferiority trial, we enrolled 184 patients hospitalized with ECOPD from 18 hospitals in Italy. Patients were assigned to receive antibiotics for 10 days (standard group) or for either 3 or 10 days (PCT group). The primary outcome was the rate of ECOPD at 6 months. Having planned to recruit 400 patients, we randomized only 183: 93 in the PCT group and 90 in the standard group. Thus, the completed study was underpowered. The ECOPD rate at 6 months between PCT-guided and standard antibiotic treatment was not significant (% difference, 4.04; 90% confidence interval [CI], -7.23 to 15.31), but the CI included the non-inferiority margin of 15. In the PCT-guided group, about 50% of patients were treated for 3 days, and there was no difference in primary or secondary outcomes compared to patients treated for 10 days. CONCLUSIONS: Although the primary and secondary clinical outcomes were no different for patients treated for 3 or 10 days in the PCT group, the conclusion that antibiotics can be safely stopped after 3 days in patients with low serum PCT cannot be substantiated statistically. Thus, the results of this study are inconclusive regarding the noninferiority of the PCT-guided plan compared to the standard antibiotic treatment. The study was funded by Agenzia Italiana del Farmaco (AIFA-FARM58J2XH). Clinical trial registered with www.clinicaltrials.gov (NCT01125098). TRIAL REGISTRATION: ClinicalTrials.gov NCT01125098., journal.pone.0118241 Background The duration of antibiotic treatment of exacerbations of COPD (ECOPD) is controversial. Serum procalcitonin (PCT) is a biomarker of bacterial infection used to identify the cause of ECOPD. Methods and Findings We investigated whether a PCT-guided plan would allow a shorter duration of antibiotic treatment in patients with severe ECOPD. For this multicenter, randomized, non-inferiority trial, we enrolled 184 patients hospitalized with ECOPD from 18 hospitals in Italy. Patients were assigned to receive antibiotics for 10 days (standard group) or for either 3 or 10 days (PCT group). The primary outcome was the rate of ECOPD at 6 months. Having planned to recruit 400 patients, we randomized only 183: 93 in the PCT group and 90 in the standard group. Thus, the completed study was underpowered. The ECOPD rate at 6 months between PCT-guided and standard antibiotic treatment was not significant (% difference, 4.04; 90% confidence interval [CI], -7.23 to 15.31), but the CI included the non-inferiority margin of 15. In the PCT-guided group, about 50% of patients were treated for 3 days, and there was no difference in primary or secondary outcomes compared to patients treated for 10 days. Conclusions Although the primary and secondary clinical outcomes were no different for patients treated for 3 or 10 days in the PCT group, the conclusion that antibiotics can be safely stopped after 3 days in patients with low serum PCT cannot be substantiated statistically. Thus, the results of this study are inconclusive regarding the noninferiority of the PCT-guided plan compared to the standard antibiotic treatment. The study was funded by Agenzia Italiana del Farmaco (AIFA-FARM58J2XH). Clinical trial registered with www.clinicaltrials.gov (NCT01125098).

Published
2015

48. Comorbidities in elderly smokers with COPD or CHF

Author

Beghé, Bianca, primary, Verduri, Alessia, additional, Garofalo, Martina, additional, Balduzzi, Sara, additional, Bortolotti, Monica, additional, Schito, Michela, additional, Clini, Enrico, additional, Fabbri, Leonardo M., additional, and Boschetto, Piera, additional

Published
2015
Full Text
View/download PDF

49. Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study

Author

Beghé, Bianca, primary, Verduri, Alessia, additional, Bottazzi, Barbara, additional, Stendardo, Mariarita, additional, Fucili, Alessandro, additional, Balduzzi, Sara, additional, Leuzzi, Chiara, additional, Papi, Alberto, additional, Mantovani, Alberto, additional, Fabbri, Leonardo M., additional, Ceconi, Claudio, additional, and Boschetto, Piera, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results